Quote:

---

On July 31, 2014, Amarantus BioScience Holdings, Inc. (the “Company”) entered into an Option Agreement (the “Agreement”) with the Universität Leipzig (“Leipzig”) pursuant to which the Company was granted an option to obtain an exclusive license (with the right to sublicense) in the patent rights relating to PCT Application No. PCT/EP2010/000702 entitled “Vector(s) Containing an Inducible Gene Encoding a CDK4/CDK6 Inhibitor Useful for Treating Neurodegenerative Disorders or Diseases Associated with an Unscheduled Activation of the Cell Cycle”. The term of the option is 12 months which may be extended by the Company for an additional six months upon payment of an extension fee of $5,000. The Agreement provides for an option fee of $10,000 within 10 days of the date of the Agreement.

The Agreement contemplates that the parties will use good faith efforts to execute a sponsored research agreement and provides that upon exercise of the option, the parties will use good faith efforts to execute a license agreement within three months of the exercise of the option.

---